全文获取类型
收费全文 | 10944篇 |
免费 | 758篇 |
国内免费 | 79篇 |
专业分类
耳鼻咽喉 | 96篇 |
儿科学 | 161篇 |
妇产科学 | 145篇 |
基础医学 | 1754篇 |
口腔科学 | 208篇 |
临床医学 | 1015篇 |
内科学 | 2373篇 |
皮肤病学 | 169篇 |
神经病学 | 1085篇 |
特种医学 | 443篇 |
外科学 | 1659篇 |
综合类 | 131篇 |
现状与发展 | 1篇 |
一般理论 | 5篇 |
预防医学 | 640篇 |
眼科学 | 316篇 |
药学 | 772篇 |
中国医学 | 25篇 |
肿瘤学 | 783篇 |
出版年
2023年 | 81篇 |
2022年 | 275篇 |
2021年 | 451篇 |
2020年 | 219篇 |
2019年 | 245篇 |
2018年 | 348篇 |
2017年 | 222篇 |
2016年 | 274篇 |
2015年 | 350篇 |
2014年 | 430篇 |
2013年 | 542篇 |
2012年 | 806篇 |
2011年 | 904篇 |
2010年 | 472篇 |
2009年 | 443篇 |
2008年 | 705篇 |
2007年 | 691篇 |
2006年 | 645篇 |
2005年 | 650篇 |
2004年 | 559篇 |
2003年 | 527篇 |
2002年 | 490篇 |
2001年 | 71篇 |
2000年 | 53篇 |
1999年 | 72篇 |
1998年 | 94篇 |
1997年 | 85篇 |
1996年 | 59篇 |
1995年 | 53篇 |
1994年 | 60篇 |
1993年 | 49篇 |
1992年 | 30篇 |
1991年 | 34篇 |
1990年 | 31篇 |
1989年 | 27篇 |
1988年 | 29篇 |
1987年 | 22篇 |
1986年 | 23篇 |
1985年 | 26篇 |
1984年 | 33篇 |
1983年 | 36篇 |
1982年 | 46篇 |
1981年 | 44篇 |
1980年 | 49篇 |
1979年 | 35篇 |
1978年 | 34篇 |
1977年 | 33篇 |
1976年 | 31篇 |
1975年 | 27篇 |
1974年 | 25篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
151.
Moraes-Filho J Cecconello I Gama-Rodrigues J Castro L Henry MA Meneghelli UG Quigley E;Brazilian Consensus Group 《The American journal of gastroenterology》2002,97(2):241-248
The Brazilian Consensus on Gastroesophageal Reflux Disease considers gastroesophageal reflux disease to be a chronic disorder related to the retrograde flow of gastroduodenal contents into the esophagus and/or adjacent organs, resulting in a variable spectrum of symptoms, with or without tissue damage. Considering the limitations of classifications currently in use, a new classification is proposed that combines three criteria-clinical, endoscopic, and pH-metric-providing a comprehensive and more complete characterization of the disease. The diagnosis begins with the presence of heartburn, acid regurgitation, and alarm manifestations (dysphagia, odynophagia, weight loss, GI bleeding, nausea and/or vomiting, and family history of cancer). Also, atypical esophageal, pulmonary, otorhinolaryngological, and oral symptoms may occur. Endoscopy is the first approach, particularly in patients over 40 yr of age and in those with alarm symptoms. Other exams are considered in particular cases, such as contrast radiological examination, scyntigraphy, manometry, and prolonged pH measurement. The clinical treatment encompasses behavioral modifications in lifestyle and pharmacological measures. Proton pump inhibitors in manufacturers' recommended doses are indicated, with doubling of the dose in more severe cases of esophagitis. The minimum time of administration is 6 wk. Patients who do not respond to medical treatment, including those with atypical manifestations, should be considered for surgical treatment. Of the complications of gastroesophageal reflux disease, Barrett's esophagus presents a potential development of adenocarcinoma; biopsies should be performed, independent of Barrett's esophagus extent or location. In this regard the designation "short Barrett's" is not important in terms of management and prognosis. 相似文献
152.
Ivan Barac Shrikanth Upadya Robert Pilchik Glenda Winson Michael Passick Farooq A Chaudhry Mark V Sherrid 《Journal of the American College of Cardiology》2007,49(11):1203-1211
OBJECTIVES: We investigated the cause of the midsystolic drop (MSD) in left ventricular (LV) ejection velocities that are observed with hypertrophic cardiomyopathy (HCM) and severe obstruction. BACKGROUND: Dynamic obstruction is an important determinant of symptoms and adverse outcome. The MSD in velocity and flow occurs in patients with gradients >60 mm Hg. The nadir velocity in the LV occurs simultaneously with peak gradient. METHODS: We studied 36 patients with obstructive HCM and an MSD and compared them with 15 patients with HCM and no obstruction and with 25 age-matched normal control subjects. We measured LV ejection velocity proximal and distal to LV obstruction as well as tissue Doppler velocities and time intervals. RESULTS: The duration of contraction of both the septum and lateral wall is shorter in obstructed patients with the MSD than in nonobstructed HCM patients: septal contraction 203 +/- 68 ms vs. 271 +/- 41 ms (p < 0.001). Parallel reduction in the length of shortening was noted: 1.2 +/- 0.6 cm vs. 1.9 +/- 0.4 cm (p < 0.001). The ejection velocity nadir follows the septal and lateral peak velocities by 100 ms and 60 ms, respectively. The velocity nadir occurs as both walls rapidly decelerate to their premature termination: septal deceleration 79 +/- 35 cm/s2 vs. 48 +/- 21 cm/s2 (p < 0.001). With medical abolition of obstruction the MSD disappears and the duration and length of contraction normalizes. CONCLUSIONS: These data indicate that the MSD is caused by premature termination of LV segmental shortening and is a manifestation of systolic dysfunction. 相似文献
153.
John P. Bantle Donald B. Hunninghake Ivan D. Frantz Kanta Kuba Cary N. Mariash Jack H. Oppenheimer 《The American journal of medicine》1984,77(3):475-481
In an attempt to compare the cholesterol-lowering effects of equivalent doses of d- and l-thyroxine, 10 euthyroid, hypercholesterolemic subjects were treated with graded doses of each medication in a cross-over design using thyrotropin suppression following thyrotropin-releasing hormone administration as the end-point. The mean thyrotropin-suppressive dose of d-thyroxine was 2.4 ± 0.66 mg per day, which resulted in mean reductions of 10 percent in total plasma cholesterol, 10 percent in plasma low-density lipoprotein cholesterol, and 11 percent in plasma high-density lipoprotein cholesterol. The mean thyrotropin-suppressive dose of l-thyroxine was 135 ± 46 μg per day, which resulted in mean reductions of 7 percent in total plasma cholesterol, 6 percent in plasma low-density lipoprotein cholesterol, and 14 percent in plasma high-density lipoprotein cholesterol. The reductions in total, low-density, and high-density cholesterol achieved with d-thyroxine were not significantly different from those achieved with l-thyroxine. Neither medication produced a significant increase in heart rate or ventricular ectopy as determined by Holter monitoring. These data do not support the belief that d-thyroxine has a preferential cholesterol-lowering effect in humans when compared with equivalent doses of l-thyroxine. In addition, both d- and l-thyroxine reduced plasma high-density lipoprotein cholesterol. 相似文献
154.
Ivan A. Friedrich M.D. Gary P. Wormser M.D. Edward B. Gottfried M.D. 《The American journal of gastroenterology》1982,77(2):82-85
We prospectively studied five patients with a remote history of Streptococcus bovis bacteremia who had not previously been evaluated for colonic pathology. This study was prompted by several reports of concomitant neoplasia in patients with recent S. bovis bacteremia. The patients were studied at a mean of 32 months after bacteremia. Despite the absence of other signs or symptoms suggestive of bowel disease, a negative test for occult blood in stool and a negative fecal culture for S. bovis , two patients were found to have neoplastic polyps of the colon. These findings suggest that the risk of colonic neoplasia in patients with remote S. bovis septicemia is similar to that found in patients with recent bacteremia, but evaluation of a larger group of these patients will be necessary to establish this risk. 相似文献
155.
156.
Jeffrey A Goldstein Ivan P Casserly David T Balzer Richard Lee John M Lasala 《Catheterization and cardiovascular interventions》2003,59(2):238-243
The initial therapy for postmyocardial infarction ventricular septal defects is surgical repair of the defect. Unfortunately, a significant number of patients develop recurrent ventricular septal defects (VSDs) following operative repair. Transcatheter closure offers an alternative to reoperation in these critically ill patients. We present a series of four patients in whom recurrent ventricular septal defects were closed using an Amplatzer VSD device. 相似文献
157.
158.
Bank I Libourel EJ Middeldorp S Van Pampus EC Koopman MM Hamulyák K Prins MH Van Der Meer J Büller HR 《Archives of internal medicine》2004,164(17):1932-1937
BACKGROUND: The prothrombin 20210A mutation has been associated with an increased risk of venous thromboembolism (VTE). Its relationship with arterial disease and pregnancy-related complications is, however, still uncertain. The aim of this study was to estimate the incidences of first venous and arterial thrombotic events and pregnancy-related complications in relatives of patients with the mutation. METHODS: After clinical classification, the presence of the mutation was determined in first-degree relatives of consecutive patients with the mutation and a history of VTE or premature atherosclerosis. Relatives with and without the mutation were compared. RESULTS: Of all relatives, 204 (50%) were heterozygous, 5 were homozygous, and 198 had a normal genotype. The annual incidence of a first episode of VTE was 0.35% and 0.18% in carriers and noncarriers, respectively (odds ratio [OR], 1.9; 95% confidence interval [CI], 0.9-4.1); the annual incidence of a first arterial thrombosis was 0.22% and 0.15% in carriers and noncarriers, respectively (OR, 2.3; 95% CI, 0.8-6.3). The annual incidence of a first myocardial infarction was 0.14% (95% CI, 0.05%-0.23%) and 0.05% (0.01%-0.14%) in carriers and noncarriers, respectively (OR, 4.7; 95% CI, 1.0-22.5; P =.06). In particular, homozygous carriers were at increased risk of VTE (OR, 6.0; 95% CI, 1.3-27.2), whereas a history of VTE in the proband influenced the risk of VTE in the relatives. Women with the mutation did not experience significantly more pregnancy-related complications than their relatives with a normal genotype. CONCLUSIONS: The prothrombin mutation is a mild risk factor for VTE within families of carriers but does not seem to play an important role in arterial thrombotic disease, with the exception of myocardial infarction, or in pregnancy-related complications. 相似文献
159.
Jaime PalomaresMarin Luis Humberto GoveaCamacho Vania AraujoCaballero Gerardo CazarezNavarro Sergio Yair RodriguezPreciado Enrique OrtizHernandez Erika MartinezLopez Jose Francisco MuozValle Ivan Isidro HernandezCaaveral 《Journal of clinical laboratory analysis》2021,35(4)
BackgroundRecurrent respiratory papillomatosis (RRP) is a respiratory tract disease that affects children and adults and is characterized by the recurrent proliferation of multiple papillomas. The etiologic agent is the human papillomavirus, mainly genotypes 6 and 11. Furthermore, polymorphisms in TAP1 appear to influence the selection of antigenic peptides and the transport process to the rough endoplasmic reticulum, for their subsequent presentation to T lymphocytes, an essential process against viral diseases and tumor processes. Previous studies have shown that individuals with those polymorphisms are susceptible to immune, infectious, and tumor‐related diseases. The present study aimed to determine the association between the TAP1 rs1057141 (c.1177A>G) and rs1135216 (c.2090A>G) single nucleotide polymorphisms (SNPs) and RRP.MethodsA case–control study was carried out on a group of 70 individuals (35 controls and 35 patients). RRP diagnosis, HPV genotyping, and viral load were determined through histology and PCR. SNPs rs1057141 and rs1135216 were identified through allelic discrimination, using real‐time PCR. The haplotypic analyses were performed using the Arlequin 3.5 program.ResultsHPV‐6 and HPV‐11 were the genotypes found in the samples. In the polymorphism analysis, rs1057141 showed no significant differences (p = 0.049, CI = 0.994–7.331). In contrast, a significant difference was found in rs1135216 (p = 0.039, OR = 2.4) in the allelic analysis, as well as in the dominant (p = 0.027, OR = 3.06), codominant (p = 0.033, OR = 3.06), and additive model (p = 0.043, OR = 2.505) in subjects with the G allele.ConclusionThe G allele in rs1135216 was associated with a genetic risk of susceptibility for RRP in a population in Western Mexico. 相似文献